Arletta Pharma Solutions

Executive Summary

Arletta Pharma Solutions is a Netherlands-based biopharmaceutical company dedicated to addressing the unmet medical need in female sexual dysfunction, specifically Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Interest/Arousal Disorder (FSIAD). Founded in 2018, the company leverages over 15 years of neurobiological research to develop therapies that modulate sexual excitation and inhibition pathways. Its lead candidate, Lybrido, is a novel combination therapy designed to restore sexual desire and arousal in women, targeting a condition that affects millions worldwide but lacks approved treatments in many regions. Arletta's focus on this underserved market positions it as a potential pioneer in women's sexual health, a historically overlooked area in pharmaceutical R&D. Lybrido represents a differentiated approach by addressing the underlying neurobiology of sexual dysfunction rather than solely hormonal factors. The company's strategy involves advancing Lybrido through clinical trials with the goal of demonstrating efficacy and safety. If successful, Lybrido could become a first-in-class therapy for HSDD/FSIAD, offering a new option for patients who have limited alternatives. However, as a private company with no disclosed financials or pipeline beyond Lybrido, Arletta faces typical early-stage risks, including regulatory hurdles, funding requirements, and commercial uncertainty. The company's progress will depend on clinical outcomes, regulatory feedback, and strategic partnerships to bring Lybrido to market.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 2/3 Clinical Trial for Lybrido in HSDD40% success
• TBDPre-IND Meeting with EMA or FDA for Lybrido60% success
• TBDStrategic Partnership or Licensing Agreement for Lybrido Commercialization35% success